Drugmakers Novo Nordisk, Daiichi-Sankyo, Lundbeck, AstraZeneca, UCB and Biogen have been named and shamed by the UK pharma trade group. 12 December 2022
Just a week after securing an historic US approval for its one-time hemophilia B treatment, Hemgenix (etranacogene dezaparvovec-drlb), Dutch gene therapy compan 30 November 2022
A Phase II miss for CinCor Pharma has sent the firm’s stock falling precipitously. Shares are now changing hands for around $14, 45% lower than last week. 29 November 2022
Novartis has presented new data on Leqvio (inclisiran), an siRNA product approved in primary hyperlipidemia as an adjunct to diet and maximally tolerated statin 8 November 2022
Continued growth in the major market for heart failure treatments looks assured for British pharma major AstraZeneca, with more positive data for its metabolic 8 November 2022
Sales and income were both down at Swiss pharma giant Novartis for the third quarter of 2022, with the company missing analyst estimates on both measures. 25 October 2022
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.